English

Nordic Nanovector ASA: Mandatory notification of trade - primary insiders

Report this content

On 9 December 2016, Ludvik Sandnes, who is the chairman of the board of directors Nordic Nanovector ASA (the "Company") purchased 1000 shares in the Company at an average price of NOK 115.00 per share. Following this transaction, Ludvik Sandnes owns 126,000 shares in the Company and holds 21,604 restricted stock units in the Company.

This information is subject to duty of disclosure pursuant to Section 4-2 of the Norwegian Securities Trading Act

  

Tags:

Cancer Therapy non-hodgkins lymphoma Betalutin Nordic Nanovector Radioimmunotherapy Roy Hartvig Larsen anticancer therapeutics

Subscribe